Skip to main content
Yixintang Pharmaceutical Group Co., Ltd. logo

Yixintang Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002727 ISIN · CNE100001WJ8 LEI · 300300NE1YJT00E9JD69 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 2,825 across all filing types
Latest filing 2026-05-22 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002727

About Yixintang Pharmaceutical Group Co., Ltd.

https://www.hx8886.com

Yixintang Pharmaceutical Group Co., Ltd. operates an extensive network of retail pharmacies providing a broad spectrum of healthcare products and services. The company specializes in the distribution of Western pharmaceuticals, traditional Chinese medicine (TCM), medical equipment, and health supplements. Its operational model integrates physical storefronts with digital platforms to facilitate online-to-offline (O2O) services, including prescription fulfillment and health consultations. Key offerings include chronic disease management, professional pharmaceutical advice, and a diverse inventory of over-the-counter (OTC) medications. The company focuses on community-based health accessibility, utilizing a robust supply chain to ensure product quality and availability across its service regions.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 91% confidence The document is a corporate announcement detailing the implementation of the 2025 annual equity distribution (cash dividend) scheme: it specifies the dividend per share, total amount, record date, ex-dividend date, tax treatment, and payment method. This matches the definition of a Notice of Dividend Amount, not a full financial report or regulatory certification. Therefore, it should be classified as Code DIV.
2026-05-22 Chinese
北京市竞天公诚律师事务所关于一心堂药业集团股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 78% confidence The provided text is a legal opinion letter issued by a law firm concerning the 2025 Annual General Meeting of shareholders (AGM) of Yixintang Pharmaceutical Group Co., Ltd. It certifies compliance with Chinese company law and listing rules, outlines the convening procedures, attendance, voting procedures, and results, and gives a legal conclusion. This is not the AGM materials or presentations (AGM-R), nor a pure declaration of voting results by the company (DVA), but rather a compliance/legal document. Therefore, it falls under the catch‐all Regulatory Filings category (RNS) for official compliance and certification letters.
2026-05-20 Chinese
2025年年度股东会暨中小投资者表决结果公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as the “2025年年度股东会暨中小投资者表决结果公告” and contains the detailed voting results of each proposal at the Annual General Meeting (AGM), including percentages of votes for, against, and abstentions. It does not present financial statements or narrative management discussion but strictly reports voting outcomes. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements.
2026-05-20 Chinese
关于使用部分暂时闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 65% confidence The document is a corporate stock exchange announcement concerning the company’s progress in deploying temporarily idle self‐owned funds into cash management products. It details amounts, counterparties, risk controls, and past 12‐month history. It is not a financial report (annual, interim) nor a dividend, M&A, or share issue notice. It relates to treasury/capital management activities, fitting the “Capital/Financing Update” category.
2026-05-19 Chinese
关于使用部分暂时闲置自有资金进行现金管理的进展公告
Regulatory Filings Classification · 75% confidence The document is an official progress announcement (公告) detailing the company’s use of temporarily idle self-owned funds for cash management – listing bank contracts, investment amounts, yields, risk analysis, and prior 12-month usage history. It is not a financial report itself (e.g., 10-K, IR), not an earnings release, board change, dividend notice, or other specialized category. It falls under general regulatory disclosures required by the exchange. Therefore it is classified as a Regulatory Filing (RNS).
2026-05-14 Chinese
关于使用部分暂时闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from YXT Health (一心堂药业集团股份有限公司) regarding the progress of using temporarily idle own funds for cash management. It details the amounts invested, types of financial products, contract dates, expected yields, risk analysis, and impact on the company. The document includes tables of investments, returns, and contracts with banks, and mentions compliance with Shenzhen Stock Exchange disclosure requirements. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript, board change, or legal proceeding. It is a specific update on capital/financing activities related to cash management and investment of idle funds. The document length is 8806 characters, which is substantive and contains detailed financial data about cash management investments. Therefore, the best fitting category is Capital/Financing Update (CAP).
2026-05-06 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.